• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Heterogeneity of immune control in chronic hepatitis B virus infection: Clinical implications on immunity with interferon-α treatment and retreatment

    2022-11-05 03:54:04GuoQingYinKePingChenXiaoChunGu
    World Journal of Gastroenterology 2022年40期

    Guo-Qing Yin,Ke-Ping Chen,Xiao-Chun Gu

    Abstract Hepatitis B virus (HBV) infection is a global public health issue. Interferon-α (IFNα) treatment has been used to treat hepatitis B for over 20 years, but fewer than 5%of Asians receiving IFN-α treatment achieve functional cure. Thus, IFN-α retreatment has been introduced to enhance antiviral function. In recent years,immune-related studies have found that the complex interactions between immune cells and cytokines could modulate immune response networks, including both innate and adaptive immunity, triggering immune responses that control HBV replication. However, heterogeneity of the immune system to control HBV infection, particularly HBV-specific CD8+ T cell heterogeneity, has consequential effects on T cell-based immunotherapy for treating HBV infection.Altogether, the host’s genetic variants, negative-feedback regulators and HBV components affecting the immune system's ability to control HBV. In this study,we reviewed the literature on potential immune mechanisms affecting the immune control of HBV and the clinical effects of IFN-α treatment and retreatment.

    Key Words: Hepatitis B virus; Chronic; Functional cure; Heterogeneity; Immunity;Immune control; Interferon-α; Retreatment

    INTRODUCTION

    Hepatitis B virus (HBV) infection is a major global health problem. It is estimated that over 257 million people are suffering from chronic hepatitis B (CHB) infection[1]. After being infected by HBV, the virus transfers its genome into the nucleus of hepatocytes, where it is converted into covalently closed circular DNA (cccDNA), which has two major roles: Acting as a template for virus replication and acting as a reservoir for long-term virus preservation. Some studies have found that cccDNA persists in the hepatocytes of patients even decades after HBV infection has been resolved[2]. Further, it was shown that part of the viral genome remained integrated into the genomic DNA of the host’s hepatocytes.Therefore, targeted eradication of cccDNA and viral genome in hepatocytes is regarded as the holy grail for curing HBV[3-5], which has not yet been achieved with current therapies.

    HBV infection induces various immune responses that lead to heterogeneous immune control associated with the HBV infection[5,6]. Acute HBV infection can be terminated by the host’s adaptive immune responses, characterized by multi-specific and vigorous HBV-specific CD8+T cell responses. In contrast, during CHB infection, the adaptive immune responses are severely depressed due to exhausted or reduced HBV-specific CD8+T-cells[6,7]and dysfunctions in HBV-specific B cells[7-9].Researchers have noticed different outcomes from HBV infection in different populations and races.

    Most CHB cases in the Asian population occur during infancy or childhood. However, asymptomatic infection during childhood makes it very challenging for authorities to determine when the infection actually occurred. Further, due to the uncertain timing of hepatitis flares and disease phases, there is little research on this topic in past literature, and little is known about hepatitis flares and intrahepatic immunity. Recently, studies on the partial immune mechanism in CHB have been performed, and important discoveries were made[2-6].

    Currently, CHB is treated with nucleoside/nucleotide analogs (NAs) or interferon-α (IFN-α). NAs can target HBV polymerase/reverse transcriptase, inhibit HBV replication and are better tolerated by patients, but they cannot target cccDNA and unavoidably often results in NAs resistance and associated mutations. Since NAs do not directly influence immune response, functional cure with NAs is rarely achieved. In contrast, IFN-α treatment enhances HBV-specific immune control and can result in a partial or functional cure. However, due to poor efficacy with single course IFN-α treatment, since 1996,researchers have begun using IFN-α retreatment to improve the antiviral efficacy in CHB patients[10-15]or sufferers from NAs multi-drugs resistance[15-18].

    In this present article, we reviewed the complex interactions between immune cells and cytokines of the immune response network against HBV, the correlation between host genetic variations and hepatitis B, the interplay between HBV components and HBV-specific immune control, and the heterogeneity of HBV-specifical immune control. Based on this foundation, we also discussed the underlying mechanism of IFN-α treatment and retreatment for improved HBV-specific immune control.

    HETEROGENEOUS IMMUNITIES DURING HBV INFECTION

    The innate and adaptive immunity work together to control immune responses against HBV. Innate immunity is not HBV antigen-specific but still produces T-cell polarizing and inflammatory cytokines that alter the intrahepatic microenvironment for presenting HBV antigens to na?ve T cells to establish HBV-specific immunity. In recent years, researchers have recognized adaptive immunity as a crucial player for persistent and efficient immune control of HBV infection, which comprises a complex web of effector cell types. HBV-specific T cells help clearing HBV-infected hepatocytes and reduce the levels of circulating virus, while B cells neutralize viral particles and prevent reinfection[3,19-22]. Thus, their levels ultimately determine the outcome of the disease.

    The liver is an immunologically tolerant organ in which most immune cells are suppressed to limit hypersensitivity of immune responses against organ damage and local antigens. Thus, in a healthy state,the proportion of immune cells within the liver is much lower than in the peripheral blood. The difference in immune statuses between the liver and peripheral blood is defined as “immune compartmentalization”. Investigations into the effects of costimulation have shown that Toll-like receptors(TLRs) and Treg cells participate in the intrahepatic immunopathogenesis in patients with HBV infection[3,23-25].

    Recognition of HBV components by the innate immunity

    Non-specific recognition of HBV components occurs at the molecular/subcellular level by innate immunosensors, namely pathogen-recognition receptors (PRRs) that recognize pathogen-associated molecular patterns (PAMP). The main PRRs that sense viral infection consists of retinoic acid-inducible gene I (RIG-I)-like receptors, nucleotide-binding oligomerization domain-containing protein-like receptors, TLRs, DNA-sensing receptors and C-type Lectin. These PRRs are expressed in epithelial cells,endothelial cells and immune cells. When PRRs interact with their cognate PAMP, downstream signaling pathways cascade, including adaptor/co-adaptor molecules, kinases and transcription factors are activated. This leads to the expression of interferon-stimulated genes (ISGs) and NFκB-inducible or pro-inflammatory genes, and various inflammatory cytokines are secreted. Primary cytokines include various classes of IFNs, pro-inflammatory cytokines and chemokines. These cytokines recruit various immune cells to the HBV-infected site, causing direct or indirect antiviral actions. These immune responses induce T cell proliferation and increase the efficiency of HBV-specific CD8+ T cells[21,26,27].In particular, TLRs in hepatocytes and hepatic non-parenchymal cells (NPCs) have been shown to play vital roles in antiviral immunity. Currently, the use of TLR agonists as therapeutic agents to treat CHB is being validated[7].

    In addition to cytokines, innate effector cells also participate in the control of HBV infection. Innate effector cells, including natural killer (NK) cells, γδT cells and mucosal-associated invariant T cells, can restrain the virus but are not specific for controlling HBV. Activated NK cells can induce inflammation in the liver, while activated T cells can be killed by NK cells, thereby reducing HBV-specific T cells.Although NK cells can suppress HBV replication, their activity was shown to be inhibited by transforming growth factor β (TGF-β) and IL-10 in CHB patients[3]. In addition, hepatic PCs, such as KCs and liver sinusoidal endothelial cells, can stimulate innate and adaptive immunity against HBV infection[28,29].

    In short, the activation of innate immunity can lead to the production of cytokines, enhance antigen presentation, alter the intrahepatic microenvironment and trigger adaptive immunity (Figure 1).

    HBV infection and adaptive immunity

    HBV-specific T cells play a vital role in controlling HBV infection, and their immune responses can lead to the resolution of HBV replication. In acute hepatitis B patients, spontaneous viral clearance can occurviamulti-specific CD8+T cell responses against HBV components[3,30]. In contrast, in CHB, the patients suffer from the exhaustion of HBV-specific CD8+T-cell responses throughout the HBV infection. Thus,most research on immune dysfunction focus on the activity of T cells, including CD8+and CD4+T-cells.

    CHB is associated with the exhaustion of HBV-specific CD8+T-cells, marked by compromising functionality, such as reduced production of antiviral cytokines and immunodulatory cytokines and impaired proliferative capacities, defined as T-cell exhaustion[31,32]. HBV-specific CD8+T-cell exhaustion can be induced by: (1) Gradual aggravation of CD8+T-cells dysfunction and decreasing inflammatory cytokines production; (2) Increase in checkpoint inhibitors and immunosuppressive cytokines; (3) Epigenetic alterations leading to unrecoverable CD8+T-cell functions; (4) Alterations in CD8+T-cell phenotype; (5) Mitochondrial dysfunction and glycolysis downregulation, (6) Decrease in cell detection rate; and (7) Terminal exhaustion and physical deletion of HBV-specific CD8+T-cells.

    In acute hepatitis B, CD4+T-cells have an important but indirect role in cleaning the virus. Th1-polarized CD4+T-cells regulate and maintain CD8+T-cell responses, contributing to HBV clearance. In contrast, during chronic HBV infection, the activation and upregulation of CD4+CD25+Treg-cells suppress effective antiviral immune responses by inhibiting IFN-γ secretion, which inhibits the proliferation and cytokine secretion of CD4+and CD8+T-cells[7,30]. Figure 1 illustrates the complex interactions between immune cells and cytokine within the immune response network. The immune cells and their related cytokines are presented in Table 1.

    HBV components inhibit innate and acquired immunity

    HBV is believed to have existed in the human population for thousands of years and evolved with humans. During this evolution process, HBV has developed a particular lifecycle based on its unique replication mode through cccDNA and viral components that can adapt and suppress its host's immunity. Although the innate immunity can differentiate between different HBV components, HBV virion, antigens and peptides are still able to attack the TLR signaling pathway, resulting in negligible ISGs or IFNs secretions[4,7].

    Table 1 Immune cells and their corresponding cytokines released

    Among the ISGs is the apolipoprotein B editing complex (APOBEC) gene. APOBEC3A/B has been shown to cause cccDNA degradation, while APOBEC3G can inhibit HBV replication. However,APOBEC3G expression is often reduced by HBsAg[32].

    A viral protein known for influencing HBV replication is HBx. It can interact with the cellular proteins in hepatocytes to increase viral replication by impairing IFN signaling and enhancing HBV gene expression[33-35]. Further, it was shown that HBV antigens could inhibit CD8+T-cell efficiency.Antagonist functions may provide a means for HBV to escape immune detection. Considering that certain CD8+T-cell epitopes in hepatitis B core antigen (HBcAg) or HBsAg can act as T-cell receptor(TCR) antagonists, their binding to TCR can lead to the suppression of CD8+T-cell response, thus decreasing their efficiency (Figure 2). In addition, the chronicity of HBV infection was shown to be promoted by HBeAgviathe induction of CD8+T-cell tolerance[36].

    Mechanisms of immune escape in antigen-presenting cells/HBV specific-CD8+ T-cells

    When the HBV protein is swallowed by antigen-presenting cells (APCs), this protein is digested into tiny pieces, which are transferred onto human leukocyte antigen (HLA) antigens. The HLA antigen complex on APCs is then displayed to T cells, which produce effector molecules to eliminate HBV.However, when HBV enters a hepatocyte, it enhances intracellular survival at the expense of higher levels of HBV replication. Thus, HBV-infected hepatocytes produce a large number of HBV antigens that can, in turn, inhibit HBV antigen processing and presentation in APCs. Further, amino acids flanking the viral epitopes in APCs play a critical role in antigen processing. Mutations at these regions in HBV infection harm the proteasomal processing of epitopes and lead to CD8+T-cell escape[30].

    HLA genes are critical for the immune system as they control pathogens and clear infections. Host HLA polymorphisms have been demonstrated to influence disease progression in HBV infection[37].Studies found that changes in the surface expression of HLA class I complexes on APCs were associated with HBV replication and persistence. Lower HLA class I expression led to early HBeAg seroconversion, while down-regulation of HLA class II molecules led to pre-core mutants of HBcAg[38].Lumleyet al[30]focused on the interplay between the immune escape of HBV and the selective mutation of HLA-binding residues. They reported that this selective mutation of HLA-binding residues in CD8+epitopes could induce the immune escape of HBV, which is one of the most commonly identified mechanisms for HBV-specific CD8+immune escape[30].

    N-linked glycosylation (NLG) is a post-translational modification that can impact the infectivity and antigenicity of HBV. It can mask immune epitopes, leading to immune escape and interfering with the antibody recognition of hepatitis B surface antigen. NLG can also affect the ability through which the envelope protein of HBV interacts with the surface of capsids to drive HBV virion secretion[30].

    The connection between TCR on T-cell and HLA class I/peptide complexes induces the activation of CD8+T-cells, but alterations in TCR recognition,i.e., epitope mutations in TCR contact residues, can lead to the immune escape of CD8+T-cells. Immunodominance of HBV epitopes is ensured by the amino acid sequence of the peptide and its concentration and binding affinity with T cell clones. In different CD8+T-cell clones, the same viral peptide can induce different signaling cascades[22]. Figure 2 illustrates the immune escape of HBV, which can occur through multiple pathways. This has a vital role in HBV infection that can last for decades, with some T cell defects being irreversible.

    Figure 1 Crosstalk among immune cells and cytokines in hepatitis B virus infection. The complex interactions among immune cells and cytokines in chronic hepatitis B are shown. Hepatitis B virus (HBV)-specific CD8+ T-cells are activated by monocytes and CD4+ T-cells, followed by recruitment and activation of macrophages by active CD8+ T-cells. The activation of natural killer (NK) T-cells is induced by Kupffer cells, which activate NK cells and hepatic stellate cells (HSCs).Suppressive Tregs, Bregs and Kupffer cells induce the functional impairment of CD8+ T cells, CD4+ T-cells and NK cells. Moreover, Treg cells, Kupffer cells and myeloid-derived suppressor cells can lead to the exhaustion of CD8+ T-cells and NK cells. Inflammatory and inhibitory cytokines, including Monocyte chemoattractant protein-1, tumor necrosis factor-α, interferon-γ, interleukin (IL)-4, IL-6, IL-12, IL-13, IL-17, IL-10, and transforming growth factor-β, are involved in the crosstalk among immune cells. The activation of HSCs in sinusoids is induced by a complement protein such as C5a. Finally, decreasing epigenetic modification and function of HBVspecific CD8+ T-cells inhibits the immune control of HBV. PD-1: Programmed death 1; CTLA-4: Cytotoxic T-lymphocyte antigen-4; IL: Interleukin; TNF-α: Tumor necrosis factor-α; TGF-β: Transforming growth factor β; IFN-γ: Interferon-γ; HSC: Hepatic stellate cell; MDSC: Myeloid-derived suppressor cells; NK: Natural killer.

    Negative feedback regulation in immune response pathways

    Negative feedback regulations commonly occur in immune response pathways. These regulations include negative regulation of immune signal pathways (i.e., negative feedback regulation in TLRs pathway), activation of immune checkpoints, expression of inhibitory cytokines, and activation of inhibitory immune cells. An active innate immunity can induce the secretion of cytokines with antiviral activity, enhance the efficiency of APCs and alter the microenvironment of the liver. However, inflammatory cytokines such as IFNs and tumor necrosis factor-α (TNF-α) can induce immune tolerance[39-41]. Many immune cells and signaling pathways in the liver contribute to immune responses against HBV infection. These immune responses are contact-dependent and can be affected by environmental factors. Inhibitory molecules are produced by hepatic stellate cells, Kupffer cells, T-regulatory cells and myeloid-derived suppressor cells. Through a contact-dependent manner, NK cells can kill HBV-specific CD8+T-cells. Moreover, HBV-specific CD8+T-cells can be suppressed by inhibitory ligands such as programmed death-ligand 1 (Figure 1)[6,42]. However, considering HBV has adaptive and active strategies to evade innate immune responses and negative feedback exists in all immune responses,immune regulator therapy targeting only a single pathway is unlikely to be effective in treating HBV infection.

    Host genetic variations associated with HBV infection

    Researchers have made great efforts to confirm the associations between HBV infection and host immunogenetics. Host genetic variants, including mutations in TLRs, HLAs, vitamin D-related genes,cytokine and chemokine genes, microRNAs, and HBV receptor sodium taurocholate co-transporting polypeptide, have been observed to impact the outcomes of HBV infection (Table 2)[43-46]. The HLA genes are divided into two classes: HLA-class I (HLA-A, B, C, E, F and G) and HLA-class II (HLA-DP,DQ, DR, DM and DO). Polymorphisms in HLA genes were shown to be significantly associated with thepathogenesis of HBV infection[47,48]. Studies have also reported that the genes encoding cytokines such as interleukins, TNF-α, IFNs and TGF-β, can influence the immune state of CHB patients[49-53]. In a study by Nitschkeet al[54], the authors confirmed that specific HLA class I alleles restricted the efficacy of HBV-specific CD8+T-cells[54], indicating that the host’s immune-related genes can affect the outcome of hepatitis B infection.

    Table 2 Host genetic variants associated with hepatitis B virus infection[43-46]

    Haplotypes:1G-A-G-A-T-T, rs9277535-rs10484569-rs3128917-rs2281388-rs3117222-rs9380343.2G-G-G-G-T-C, rs9277535-rs10484569-rs3128917-rs2281388-rs3117222-rs9380343.3A-A, rs3077-rs9277535.4A-A, rs2395309-rs9277535.5T-A-T, rs3077-rs9277378-rs3128917.6C-A-T, rs3077-rs9277378-rs3128917.7A-A-C-T, rs2395309-rs3077- rs2301220-rs9277341.8A-A-C-C//A-G-T-G-C-C, rs2395309-rs3077-rs2301220-rs9277341//rs9277535-rs10484569-rs3128917 -rs2281388-rs3117222-rs9380343.9A-A-C-T//A-G-T-G-C-C, rs2395309-rs3077-rs2301220-rs9277341//rs9277535-rs10484569-rs3128917 -rs2281388-rs3117222-rs9380343.10G-G-T-C//A-G-T-G-C-C, rs2395309-rs3077-rs2301220-rs9277341//rs9277535-rs10484569-rs3128917 -rs2281388-rs3117222-rs9380343;11T-T-G-A-T, rs9276370-rs7756516-rs7453920- rs9277535-rs9366816.12T-T-G-G-T, rs9276370-rs7756516-rs7453920-rs9277535-rs9366816.13G-A, rs2856718- rs9275572.14A-G, rs2856718- rs9275572.15A-A, rs2856718- rs9275572.16T-C-C-G-G-G, -1031/-863/-857/-308/-238/-163.17C-A-C-G-G-G, -1031/-863/-857/-308/-238/-163.18A-T-G-T-T-T-T-C-T, +88344/+102906/+103432/+103437/+103461/+104261/+104802/+106151/+106318.19T-C, rs12375841-rs17803780.20C-A-C, rs421446-rs107822-rs213210.21T-G-T, rs421446-rs107822-rs213210.22C-A-C-C-G, -1722/-1661/-658/-319/+49.23T/C-A-C-C-G, -1722/-1661/-658/-319/+49.24T-A-C-C-A, -1722/-1661/-658/-319/+49.25A-T-A, rs17401966-rs12734551-rs3748578.26C-C, rs111033850-rs12953258.27T-T-C-T-A, -1800/-1627/+4645/+5806/+6139.28C-T-C-T-T, rs8179673-rs7574865-rs4274624-rs11889341-rs10168266.29G-G-A, rs3757328-rs6940552-rs9261204.SNPs/Hap/CNVs: Single nucleotide polymorphisms/Haplotype/Copy number variations; HLA: Human leukocyte antigen; TLR: Toll-like receptors.

    Figure 2 Mechanism of immune escape in antigen-presenting cell/hepatitis B virus special T-cell. Hepatitis B virus (HBV)-infected hepatocytes produce various HBV antigens that are swallowed and digested by antigen-presenting cells (APCs), producing HBV peptide/human leukocyte antigen (HLA)complexes. Antigen processing escape mutants, down-regulating HLA expression and mutation of HLA binding residues may appear in APCs. The HBV peptide/HLA complexes are transferred to the surface of APC and make contact with T-cell receptor (TCR) on the surface of CD8+ T-cells. Masking HLA/TCT binding residues with N-linked glycosylation and mutation of TCR binding residues influences TCR affinity/avidity, leading to CD8+ T-cell stimulation or inhibition. The square icon displays:(1) Increase in viral antigen; (2) Antigen processing escape mutants; (3) Down-regulation of HLA expression; (4) Mutation of HLA binding residues; (5) Masking of HLA/TCT binging residues with N-linked glycosylation; (6) Mutation of TCR binding residues; (7) Stimulation induced by cytokine production and cytolytic activity; and(8) Inhibition caused by exhaustion, anergy and tolerance. HBV: Hepatitis B virus; TCR: T-cell receptor; HLA: Human leukocyte antigen.

    Researchers have observed significant differences in HBV infection rates between Western and East/Southeast Asian populations. Prior to HBV vaccination programs, the prevalence of HBsAg was less than 1% in the Caucasian population but higher than 10% in the Chinese population[43]. This difference was investigated in several studies, which showed that HLA molecules in European,Caucasian, Middle East, African-American and Asian populations affected the rate of HBV infection[43,55,56]. In addition, discordances in HBV-specific CD8+T-cell repertoires observed in different races, i.e.,between Chinese and Caucasian populations, could be related to race-dependent HLA gene variants,leading to the different T-cell responses observed between different populations and ethnicities[57].

    Thus, these findings underline the complexity of HBV-specific immune control efficacy, which is influenced by HBV components, negative feedback regulation in immunity and host genetic variants(Figure 3).

    Heterogeneity of immune control in HBV infection

    Figure 3 Interplay between hepatitis B virus-specific immune control, hepatitis B virus components, and negative feedback regulation in immunity and host genes. HBV: Hepatitis B virus.

    Heimet al[6]reviewed the heterogeneity of HBV-specific CD8+T-cells and described the functional deficiencies and distinct phenotypical characteristics associated with HBV-specific CD8+T-cells exhaustion. T-cell impairment demonstrates hierarchical and progressive loss in antiviral functions,from functional suppression to physical deletion in T-cells, which depend on the quantity of HBV antigens and the duration of T cell exposure to these antigens[31,58]. Moreover, exhausted CD8+T-cells do not represent a homogeneous T-cell population but are rather heterogeneous in function and phenotype. Kuiperyet al[5]proposed concepts related to the heterogeneity of immune responses in CHB patients[5]. Based on reports from literature, we summarized the following concepts to improve our understanding on the heterogeneity of immune control.

    Figure 1 illustrates the activation and inhibition of immune signaling pathways that overlap in HBV infection, multiple immune cell populations and integrated signals pathways that simultaneously respond to the stimulation of HBV components, and the ability of HBV-specific immune control depends on the overall immune responses of an individual rather than the capability of single immune cells or a single immune pathway.

    Based on the immune escape mechanisms of APCs/CD8+T-cells presented in Figure 2, the heterogeneous immune responses of T-cells are related to very fine mechanisms of immune regulation that influence the immune control of HBV-specific T-cells, or T-cells sensitivity/inhibition.

    Figure 3 outlines the reasons for heterogeneous immune control. The overall immune control against HBV in an individual is influenced by HBV, negative feedback regulation in the immune signaling network and host genetic variants. Therefore, any changes in these three countenances could lead to fluctuations affecting the effectiveness of immune control. Thus, CHB infection is divided into four clinical phases: Immune tolerant with HBeAg-positive, HBeAg-positive immune-activation, inactive carrier with HBeAg-negative, and HBeAg-negative immune-activation. Further, heterogeneous immune controls can lead to different clinic phases and disease outcomes such as acute hepatitis, chronic hepatitis, cirrhosis, hepatocellular carcinoma and hepatic failure[43].

    Reports have shown that host genetic polymorphisms are crucial determinants influencing HBV infectious rate and disease outcomes in Caucasian, Saudi Arabian, African-American, European, and Asian populations[56,59,60]. In addition, the host genetic variants of individuals from the same race can influence disease outcomes and the efficacies of antiviral therapy.

    Researcher and immunologists who often overlook immune compartmentalization should be cautious when interpreting findings from the peripheral blood of patients.

    IFN-α TREATMENT FOR CHB

    Definition of partial cure and functional cure

    A complete cure from HBV infection is currently hypothesized to be possible if the cccDNA and integrated HBV DNA are eliminated from hepatocytes. However, this is challenging as cccDNA can still persist in patients despite spontaneous recovery from an acute HBV infection. Since 2017, some advances in CHB therapeutics have been achieved[61], and researchers have proposed new definitions of cure. For instance, a partial cure has been defined as persistently undetectable HBV DNA and HBeAg in patients’ serum after the completion of a limited course of antiviral therapy. Functional cure has been defined as sustained and undetectable HBV DNA and HBsAg in patients’ serum, with or without seroconversion to hepatitis B surface antibody (anti-HBs), after a limited course of therapy. Complete sterilizing cure has been defined by the absence of HBsAg and eradication of HBV DNA, including HBV virion, integrated HBV DNA and cccDNA in the liver and serum of patients. However, because current treatments cannot deliver complete sterilizing cure, functional cure is the selected goal of therapy.

    NAs and immunotherapy

    Therapeutic strategies for CHB can be classified into two categories: NAs targeting HBV replication and immune modulators targeting immune control. NAs can cause rapid decay of HBV DNA in the peripheral blood but cannot completely eradicate HBsAg from patients' serum and cccDNA in hepatocytes[62,63]. Even though the virus might be undetectable in the serum after long-term treatment with NAs, low-level viral replication still persists due to the conservation of cccDNA in the nucleus of hepatocytes. Thus, prolonged NAs treatments are rarely associated with CHB cure and inevitably result in either NAs resistance or viral relapse[62-66].

    In contrast, immunotherapy can target the innate and adaptive immunity to reinvigorate the host immune response to long-term inhibition of viral replication. Therapeutic strategies involving innate immunity include activating pattern recognition receptors (i.e., TLRs and RIG-I), enhancing cytokine secretion, and improving the efficacy of NK cells. For adaptive immunity, therapies are directed at restoring the effects of HBV-specific T-cells and B-cells. Clinically, although immunotherapy can lead to sustained HBsAg loss, it cannot eradicate cccDNA from hepatocytes. Thus, being the more promising treatment compared to NAs, the ultimate goal of immunotherapy is currently targeted at achieving functional cure, enabling spontaneous control of HBV replication and maintaining disease remission without antiviral therapy[3]. Hoogeveen and Boonstra[32]reported that immunomodulators regulating a single immune pathway might not restore antiviral immunity as multiple immune pathways in the host enhance specific HBV immune responses[32].

    Mechanism and clinical application of IFN-α therapy

    IFNs are produced and released by immune cells in response to HBV components[67,68]. Of the known IFNs, IFN-α has broad-spectrum effects on viruses and tumors, and contributes to immune regulation by suppressing viral replication and cell growth. The antiviral function of IFN-α is cascaded by binding to IFN receptors on immune cells, activating signal transcription pathways, and inducing ISGs expression and related product secretion. Various ISGs products were found to inhibit different stages of the viral life cycle[69]. Further, epigenetics was shown to play a critical role in regulating cccDNA transcription[70-73]. IFN-α can regulate the epigenetic repression of cccDNA transcription by inducing cccDNA-bound histone hypo-acetylation and increasing the recruitment of transcription co-repressor on cccDNA[63,65,73]. In addition, IFN-α can upregulate HLAs expression to activate innate and adaptive immune responses. Many researchers have investigated the host genes associated with IFN-α treatment outcomes and observed its genetic polymorphisms[43,44,74-78](Table 3).

    As described earlier, due to negative feedback mechanisms, immune modulators targeting a single signal pathway might not improve the overall and long-term immune responses[61]. In this regard, the advantages of IFN-α treatment are that IFN-α can simultaneously affect multiple immune pathways and various immune cell populations in the host and integrate signals to improve the efficacy of immune control[10,11,15,36]. Currently, only IFN-α treatment was found to improve the efficacy of immune control[64,65].

    IFN-α has been approved for the treatment of hepatitis B for over 20 years[36,61,65]. Compared with NAs, IFN-α has shown better efficacy in HBeAg seroconversion and HBsAg loss, with no risk of drug resistance[79]. For groups of patients with good prognoses, such as Caucasians, young age, low viral load, and females, IFN-α treatment has been more effective[80,81]. One study reported functional cure in 10%-20% of Caucasians who underwent IFN-α treatment, while it was < 5% in Asian patients[82].However, most of the underlying mechanisms of IFN-α therapy are still unclear. More research is needed to investigate these significant differences in IFN-α efficacy between different groups of patients.

    Table 3 Host genetic variants associated with interferon-α therapy[43,44,74-78,91]

    IMPROVEMENT OF HBV-SPECIFIC IMMUNE CONTROL BY IFN-α RETREATMENT

    IFN-α retreatment

    In 1996, although IFN-α was already being used to treat CHB patients, only 20%-30% of the patients achieved viral suppression or partial cure with single IFN-α treatment. Then, it was found that IFN-α retreatment in these remaining patients could enhance treatment outcomes. Thus, multiple courses of IFN-α were implemented to treat these patients and researchers observed that three courses of IFN-α treatment were effective in treating HBeAg positive or negative patients. With multiple frequencies of IFN-α treatment, partial or functional cure rates gradually increased to approximately 25%-40% but were mostly observed in patients of white race[10-14](Table 4).

    By 2008, failures from combination therapy with nucleoside and nucleotide were reported, and multidrug resistance with NAs treatment started to increase in China. Comparatively, IFN-α retreatment was associated with safe stopping of NAs administration and induced better-sustained responses to IFN-α[15]. Thus, when researchers started to investigate the effects of increasing the frequency and extending the total course of IFN-α treatment and found that these could significantly improve the rate of functional cure in Asian and Caucasian patients[73-75,80-83]. IFN-α retreatment was recommended by the Asian-Pacific clinical practice guidelines[16-18]and by Yinet al[64](Table 4). Based on these promising findings and recommendations, we estimate that more CHB patients in Asia would receive IFN-α retreatment and experience better antiviral efficacy.

    Interplay between IFN-α retreatment and the HBV-specific immune control

    Recently, more and more HBV-specific immune mechanisms have been discovered, inspiring clinicians and immunologists to collaborate to study the interplay between immune mechanisms and clinical events in hepatitis B. Changet al[84]summarized the relationship between hepatitis flare and immune responses in CHB patients to explore the underlying immune mechanism of hepatitis flares[84]. The observations made from the strategy of Chang'set al[84]involved in IFN-α retreatment.

    Table 4 Summary and timeline of interferon-α retreatment for chronic hepatitis B virus infection

    Asymptomatic persistence of cccDNA in the liver of patients who had acute hepatitis B or selflimiting HBV infection, despite the resolution of HBV infection[3], indicates that the host’s immune system can fully inhibit HBV replication and that the specific HBV immune control in these individuals had an overwhelming advantage over HBV replication. In addition, investigations on the heterogeneous immune control of HBV infection have shown that the heterogeneity depends on the interplay between the host, virus and therapy, including host genes and immunity state, HBV load, duration of HBV infection, and IFN-α treatment and course of treatment[5,6,31,58]. However, the exact mechanismviawhich IFN-α retreatment exerts its benefits is yet to be fully elucidated.

    Apart from HBV load, HBsAg and HBeAg, markers associated with the immune control of IFN-α treatment are lacking. In a study by Konerman and Lok[79], the authors proposed a scoring system that could help assess the efficacy of immune control[79]. The type of immune control could be estimated from a patient’s HBV DNA, HBeAg seroconversion, HBsAg loss and times of IFN-α treatment, based on the following criteria: (1) Patients with acute hepatitis B or self-limiting HBV infection could achieve automatic cure without IFN-α treatment; (2) Patients with acute hepatitis B could achieve functional cure with one time IFN-α treatment; (3) CHB patients with one time IFN-α treatment could achieve functional cure; (4) CHB patients with one time IFN-α treatment could achieve partial cure; (5) CHB patients with multiple times of IFN-α treatment could achieve functional cure; and (6) CHB patients with multiple times of IFN-α treatment could achieve partial cure. These criteria suggest a step-like decline in immune control with increasing infection severity.

    Clinical studies have confirmed that IFN-α retreatment could gradually increase the rate of partial and functional cure (Table 4)[10,11,13,15,36]and that CHB patients often have diverse HBV-specific immune control. Since 2016, researchers in China have reported numerous findings from clinical trials in which patients with inactive HBsAg carriers or low-level viremia were selectively enrolled and treated with IFN-α to evaluate their functional cure rate[85-88]. However, it should be noted that these were performed under trial settings because clinical guidelines do not recommend IFN-α therapy for the treatment of CHB in these patients[16,89,90]. A high rate of functional cure, 44.7%-84.2% of HBsAg loss and 20.2%-68.2% of HBsAg seroconversion were reported, in which a distinctive pattern of immune control whereby a close correlation between lower HBsAg at baseline and higher rates of HBsAg loss or HBsAg seroconversion was observed[85-88]. This pattern also appeared in the final course of IFN-α retreatment in previous studies[10,11,13,15,36], indicating that reducing HBsAg could be a prerequisite for achieving functional cure during IFN-α retreatment.

    Taken together, current literature indicates that IFN-α retreatment could gradually enhance the overall immune control and improve the antiviral efficacy of IFN-α in CHB patients (Figure 4).

    Figure 4 Interferon-α retreatment improves the efficacy of hepatitis B virus-specific immune control. Interferon-α (IFN-α) retreatment can lead to various treatment outcomes, namely no response, hepatitis B virus (HBV) decline, partial cure and functional cure. Multiple frequencies of IFN-α treatment can potentially restore specific immune control to HBV infection and simultaneously increase the rate of partial cure and functional cure. A: Exhausted immune control to HBV before IFN-α therapy (Baseline); B: Without HBV decline following IFN-α therapy; C: HBV decline; D: Partial cure; E: Functional cure. CHB: Chronic hepatitis B.

    CONCLUSION

    The interactions between immune cells and cytokines form a complex immune response network that exerts immune control over HBV infection. The efficacy of HBV-specific immune control is affected by HBV components, negative feedback regulation in the immune system, host genetic variants, and heterogeneity in the function and phenotype of immune control to HBV. Treatment with IFN-α can simultaneously affect multiple immune pathways and various immune cell populations in the host and integrate signals to improve the efficacy of immune control. Clinically, increasing the frequency and extending the total course of IFN-α retreatment have improved functional cure rates, indicating that IFN-α retreatment could gradually enhance the overall immune control. Further research on IFN-α retreatment could help promote this strategy in CHB patients with.

    Altogether, this article outlined immune control without detailed discussions on immunity-related markers during immune transformation. In future studies, the discovery of detailed markers associated with immune transformation could provide important clues in understanding the underlying mechanism of immune control to improve the treatment of HBV infection.

    ACKNOWLEDGEMENTS

    We are very grateful to Prof. Gao-Jun Teng in Zhong-Da Hospital, Southeast University and Prof. Bei Zhong in the sixth Affiliated Hospital of Guangzhou medical University/Qingyuan People’s Hospital for the comprehensive evaluation of the manuscript and valuable advices. Authors acknowledge Dr.Cun Shan in the Department of infectious disease, Nanjing Zhong-Da Hospital for data collection.

    FOOTNOTES

    Author contributions:All authors contributed to the study conception and design; The first draft of the manuscript was written by Yin GQ; All authors commented on previous versions of the manuscript, they all read and approved the final manuscript.

    Conflict-of-interest statement:All the authors report no relevant conflicts of interest for this article.

    Open-Access:This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BYNC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is noncommercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

    Country/Territory of origin:China

    ORCID number:Guo-Qing Yin 0000-0002-8972-3752; Ke-Ping Chen 0000-0002-8601-7481; Xiao-Chun Gu 0000-0002-7289-8054.

    S-Editor:Fan JR

    L-Editor:A

    P-Editor:Fan JR

    狂野欧美激情性xxxx| 亚洲成人久久爱视频| 黄片大片在线免费观看| 精品午夜福利视频在线观看一区| 国产成人精品久久二区二区免费| 久久久久久九九精品二区国产 | 一本精品99久久精品77| 在线a可以看的网站| 一a级毛片在线观看| 色综合站精品国产| 久久久精品国产亚洲av高清涩受| 看片在线看免费视频| 日本黄色视频三级网站网址| 99久久精品热视频| 久久精品成人免费网站| 熟女少妇亚洲综合色aaa.| 好看av亚洲va欧美ⅴa在| 日韩免费av在线播放| 亚洲精品美女久久久久99蜜臀| 嫁个100分男人电影在线观看| 蜜桃久久精品国产亚洲av| 亚洲自偷自拍图片 自拍| 亚洲av成人不卡在线观看播放网| or卡值多少钱| 最新在线观看一区二区三区| 一区二区三区高清视频在线| 天堂√8在线中文| 高清毛片免费观看视频网站| 欧美久久黑人一区二区| 一二三四在线观看免费中文在| 国产成人系列免费观看| 久久中文字幕人妻熟女| 国产成人欧美在线观看| 激情在线观看视频在线高清| 久久99热这里只有精品18| 搡老妇女老女人老熟妇| 免费在线观看亚洲国产| 搞女人的毛片| 男人舔女人下体高潮全视频| 18美女黄网站色大片免费观看| 狂野欧美激情性xxxx| 亚洲自偷自拍图片 自拍| 久久人人精品亚洲av| 亚洲性夜色夜夜综合| 国产成人一区二区三区免费视频网站| 真人做人爱边吃奶动态| 国产男靠女视频免费网站| 九九热线精品视视频播放| 亚洲人成电影免费在线| 波多野结衣巨乳人妻| 亚洲成人久久性| www.999成人在线观看| 毛片女人毛片| 成人一区二区视频在线观看| 国产av在哪里看| 90打野战视频偷拍视频| 中亚洲国语对白在线视频| 国产亚洲精品久久久久5区| 亚洲 欧美 日韩 在线 免费| 国产高清视频在线播放一区| 国产亚洲精品第一综合不卡| 久久这里只有精品中国| 国产一区二区在线av高清观看| 狠狠狠狠99中文字幕| 午夜精品在线福利| 国产97色在线日韩免费| 91大片在线观看| 亚洲色图av天堂| 不卡一级毛片| 日本免费一区二区三区高清不卡| 午夜福利在线在线| 日韩 欧美 亚洲 中文字幕| 国产精品久久久久久精品电影| 久久久水蜜桃国产精品网| 国产亚洲精品久久久久5区| 高清毛片免费观看视频网站| aaaaa片日本免费| 丰满人妻熟妇乱又伦精品不卡| 丁香六月欧美| 欧美日韩瑟瑟在线播放| 国产高清视频在线播放一区| 久久婷婷人人爽人人干人人爱| 亚洲av日韩精品久久久久久密| 香蕉丝袜av| 又爽又黄无遮挡网站| 日本熟妇午夜| 丰满人妻一区二区三区视频av | 亚洲成人精品中文字幕电影| 国产伦人伦偷精品视频| 校园春色视频在线观看| 亚洲成人久久性| videosex国产| 国产97色在线日韩免费| 精品不卡国产一区二区三区| 久久香蕉国产精品| 可以免费在线观看a视频的电影网站| 99国产精品一区二区三区| 啦啦啦免费观看视频1| 大型av网站在线播放| 99热这里只有精品一区 | 老熟妇仑乱视频hdxx| av有码第一页| 性欧美人与动物交配| 亚洲午夜精品一区,二区,三区| 日本 av在线| 久久久久国内视频| 50天的宝宝边吃奶边哭怎么回事| 12—13女人毛片做爰片一| 午夜视频精品福利| 99久久综合精品五月天人人| 日韩欧美国产在线观看| 欧美绝顶高潮抽搐喷水| 麻豆久久精品国产亚洲av| 国产亚洲精品第一综合不卡| 亚洲成人国产一区在线观看| 久久久久久大精品| 母亲3免费完整高清在线观看| 国产真实乱freesex| 国产单亲对白刺激| 国产av麻豆久久久久久久| 亚洲av五月六月丁香网| 亚洲专区中文字幕在线| 午夜a级毛片| 91成年电影在线观看| 1024手机看黄色片| www.熟女人妻精品国产| 99热这里只有是精品50| 人人妻,人人澡人人爽秒播| 久久精品国产亚洲av高清一级| 99热这里只有精品一区 | 三级男女做爰猛烈吃奶摸视频| 免费在线观看完整版高清| 女警被强在线播放| 手机成人av网站| 欧美黄色片欧美黄色片| 国产单亲对白刺激| 亚洲成人久久性| 99国产综合亚洲精品| 欧美一级毛片孕妇| 免费在线观看影片大全网站| 一个人免费在线观看电影 | 亚洲专区国产一区二区| 亚洲精品粉嫩美女一区| 国产激情久久老熟女| 精品国产超薄肉色丝袜足j| 午夜福利免费观看在线| 国内久久婷婷六月综合欲色啪| 欧美一级毛片孕妇| 婷婷精品国产亚洲av| 一二三四社区在线视频社区8| 热99re8久久精品国产| 欧美精品啪啪一区二区三区| 男女做爰动态图高潮gif福利片| 午夜精品在线福利| 亚洲一区中文字幕在线| 国产午夜精品久久久久久| 桃色一区二区三区在线观看| 国产精品99久久99久久久不卡| 亚洲国产欧洲综合997久久,| 91麻豆av在线| 男人舔女人的私密视频| 两个人视频免费观看高清| 久久午夜综合久久蜜桃| 国产三级中文精品| 在线观看午夜福利视频| 国产午夜精品论理片| 一区福利在线观看| 热99re8久久精品国产| 成人高潮视频无遮挡免费网站| 丰满人妻一区二区三区视频av | 久久中文字幕一级| 黑人欧美特级aaaaaa片| 午夜福利欧美成人| 国产精华一区二区三区| 欧美激情久久久久久爽电影| 久久精品综合一区二区三区| 天堂影院成人在线观看| 国产精品影院久久| 黄片大片在线免费观看| 亚洲国产精品合色在线| 久久久久久大精品| 亚洲av成人精品一区久久| 男女午夜视频在线观看| 久久午夜亚洲精品久久| 国产亚洲精品av在线| 亚洲美女视频黄频| 97超级碰碰碰精品色视频在线观看| 午夜激情av网站| 亚洲av成人av| 国产成人欧美在线观看| 精品一区二区三区视频在线观看免费| 亚洲精品中文字幕一二三四区| 国产在线精品亚洲第一网站| av欧美777| av福利片在线| 亚洲欧美精品综合一区二区三区| 叶爱在线成人免费视频播放| 日日夜夜操网爽| 国产不卡一卡二| 精品欧美国产一区二区三| 熟妇人妻久久中文字幕3abv| 欧美一区二区国产精品久久精品 | 亚洲精品一区av在线观看| 久久精品成人免费网站| 亚洲欧美日韩东京热| 亚洲精品美女久久久久99蜜臀| 少妇的丰满在线观看| 国产视频一区二区在线看| 成在线人永久免费视频| 免费在线观看日本一区| 色综合亚洲欧美另类图片| 日本撒尿小便嘘嘘汇集6| 在线a可以看的网站| 最近视频中文字幕2019在线8| 国产高清videossex| 国产三级中文精品| 久久精品成人免费网站| 亚洲国产精品合色在线| 极品教师在线免费播放| 啦啦啦韩国在线观看视频| 97人妻精品一区二区三区麻豆| 久久午夜亚洲精品久久| 国产黄片美女视频| 香蕉丝袜av| 欧美一级a爱片免费观看看 | 天堂av国产一区二区熟女人妻 | 久久久国产成人精品二区| 熟女电影av网| 99久久无色码亚洲精品果冻| 91在线观看av| 日韩三级视频一区二区三区| 久久国产精品人妻蜜桃| 久久精品夜夜夜夜夜久久蜜豆 | 精品国产亚洲在线| 亚洲aⅴ乱码一区二区在线播放 | 丝袜人妻中文字幕| 亚洲一区二区三区不卡视频| 九色成人免费人妻av| 欧洲精品卡2卡3卡4卡5卡区| 亚洲自拍偷在线| 欧美成狂野欧美在线观看| 亚洲自偷自拍图片 自拍| 哪里可以看免费的av片| 国产av一区在线观看免费| 神马国产精品三级电影在线观看 | 波多野结衣高清无吗| 嫁个100分男人电影在线观看| 99久久99久久久精品蜜桃| 2021天堂中文幕一二区在线观| 中文字幕熟女人妻在线| 老鸭窝网址在线观看| 岛国在线免费视频观看| 国产精品亚洲av一区麻豆| 看黄色毛片网站| 亚洲全国av大片| 久久精品综合一区二区三区| 久久香蕉激情| 久久久精品大字幕| 在线观看www视频免费| 深夜精品福利| 欧美黑人巨大hd| 日本三级黄在线观看| 黑人操中国人逼视频| 波多野结衣高清无吗| videosex国产| 国产成人av教育| 特级一级黄色大片| 床上黄色一级片| 黄色丝袜av网址大全| 久久国产乱子伦精品免费另类| 两性夫妻黄色片| 又黄又爽又免费观看的视频| 日本免费a在线| 欧美最黄视频在线播放免费| 深夜精品福利| xxx96com| 亚洲,欧美精品.| 欧美日韩亚洲国产一区二区在线观看| 成人三级黄色视频| 国产69精品久久久久777片 | 天天添夜夜摸| 波多野结衣巨乳人妻| 岛国视频午夜一区免费看| 蜜桃久久精品国产亚洲av| 国产野战对白在线观看| 日本撒尿小便嘘嘘汇集6| 亚洲成人久久性| www.www免费av| 欧美性长视频在线观看| 免费看美女性在线毛片视频| 亚洲国产欧美网| 亚洲国产欧洲综合997久久,| 精品一区二区三区av网在线观看| 国产91精品成人一区二区三区| 老司机午夜福利在线观看视频| 91字幕亚洲| 久久九九热精品免费| av免费在线观看网站| 亚洲欧美一区二区三区黑人| 亚洲va日本ⅴa欧美va伊人久久| 欧美日韩中文字幕国产精品一区二区三区| 国产v大片淫在线免费观看| 天天躁夜夜躁狠狠躁躁| 亚洲一卡2卡3卡4卡5卡精品中文| 妹子高潮喷水视频| 给我免费播放毛片高清在线观看| 国产精品久久久久久久电影 | 日本免费a在线| 丁香六月欧美| 天堂√8在线中文| 性欧美人与动物交配| 亚洲色图av天堂| 男女之事视频高清在线观看| 脱女人内裤的视频| 国产亚洲精品第一综合不卡| 国内精品久久久久久久电影| 男人舔奶头视频| 最近在线观看免费完整版| 日韩中文字幕欧美一区二区| 91国产中文字幕| 在线观看免费视频日本深夜| 久久天躁狠狠躁夜夜2o2o| 日本熟妇午夜| 99国产精品一区二区蜜桃av| 白带黄色成豆腐渣| 中亚洲国语对白在线视频| 亚洲一区中文字幕在线| 久久亚洲真实| 老司机在亚洲福利影院| 久久天躁狠狠躁夜夜2o2o| 老熟妇乱子伦视频在线观看| 99久久无色码亚洲精品果冻| 777久久人妻少妇嫩草av网站| 搡老妇女老女人老熟妇| 天天一区二区日本电影三级| 大型av网站在线播放| 天天一区二区日本电影三级| 久久久久久久精品吃奶| 国语自产精品视频在线第100页| 成人午夜高清在线视频| 成年版毛片免费区| 国产精品久久视频播放| 久久国产精品影院| 久久久久九九精品影院| 全区人妻精品视频| 午夜精品在线福利| 欧美一区二区精品小视频在线| 久9热在线精品视频| 婷婷精品国产亚洲av| 90打野战视频偷拍视频| 天天添夜夜摸| 九九热线精品视视频播放| 国产视频内射| 在线十欧美十亚洲十日本专区| 婷婷六月久久综合丁香| 俺也久久电影网| 精品国产乱子伦一区二区三区| 亚洲精品一区av在线观看| 久久人妻福利社区极品人妻图片| 一本精品99久久精品77| 99久久久亚洲精品蜜臀av| 男人的好看免费观看在线视频 | 亚洲黑人精品在线| 亚洲精品一卡2卡三卡4卡5卡| 久久久久久久精品吃奶| 在线观看66精品国产| 中国美女看黄片| 国产亚洲av高清不卡| 高清毛片免费观看视频网站| 老汉色∧v一级毛片| 久9热在线精品视频| 两个人的视频大全免费| 国产成人一区二区三区免费视频网站| 欧美+亚洲+日韩+国产| 操出白浆在线播放| 久久精品91蜜桃| 黄片大片在线免费观看| 亚洲成人久久性| 精品熟女少妇八av免费久了| 婷婷精品国产亚洲av在线| 非洲黑人性xxxx精品又粗又长| 国产精品久久久久久亚洲av鲁大| 黄片大片在线免费观看| 国产伦在线观看视频一区| 久久久国产欧美日韩av| av在线天堂中文字幕| 国产精品永久免费网站| 日韩免费av在线播放| 久久精品成人免费网站| 国产免费男女视频| 国产高清视频在线观看网站| 亚洲av电影不卡..在线观看| 久久精品人妻少妇| 欧美zozozo另类| 久久久久久久久中文| 久久精品国产清高在天天线| 日韩大码丰满熟妇| 欧美乱色亚洲激情| 午夜a级毛片| 最近在线观看免费完整版| 国产精品乱码一区二三区的特点| 一进一出好大好爽视频| 在线看三级毛片| 不卡一级毛片| 夜夜爽天天搞| 在线观看舔阴道视频| 长腿黑丝高跟| 在线播放国产精品三级| 亚洲成人精品中文字幕电影| 久久香蕉激情| 一级黄色大片毛片| 欧美日韩乱码在线| 国产精品野战在线观看| 久久精品国产清高在天天线| 久久久久国产一级毛片高清牌| 日韩精品青青久久久久久| 久久久久九九精品影院| 亚洲色图av天堂| 香蕉丝袜av| 日日爽夜夜爽网站| 亚洲 国产 在线| 一个人免费在线观看电影 | 国产97色在线日韩免费| 12—13女人毛片做爰片一| 欧美日韩亚洲综合一区二区三区_| 午夜福利成人在线免费观看| 18禁观看日本| 国产亚洲av嫩草精品影院| 超碰成人久久| 国产一区二区三区在线臀色熟女| 精品国内亚洲2022精品成人| 黄色女人牲交| 特大巨黑吊av在线直播| 国产精品影院久久| 又大又爽又粗| 黄色毛片三级朝国网站| 五月伊人婷婷丁香| 国产亚洲av嫩草精品影院| 国内精品一区二区在线观看| 亚洲av电影在线进入| 亚洲av成人精品一区久久| 久久精品国产亚洲av香蕉五月| 国产精品亚洲av一区麻豆| 日韩欧美国产一区二区入口| 亚洲一卡2卡3卡4卡5卡精品中文| 欧美成人午夜精品| 国产精品久久久久久人妻精品电影| 一本综合久久免费| 国产精品自产拍在线观看55亚洲| 色老头精品视频在线观看| 18禁裸乳无遮挡免费网站照片| 亚洲精品中文字幕在线视频| 97超级碰碰碰精品色视频在线观看| 啦啦啦免费观看视频1| 久久久久精品国产欧美久久久| 一二三四社区在线视频社区8| 色综合婷婷激情| 日日干狠狠操夜夜爽| 精品不卡国产一区二区三区| 国产成人aa在线观看| 欧美av亚洲av综合av国产av| 中文字幕最新亚洲高清| 国产一区二区在线av高清观看| 国产伦在线观看视频一区| 97超级碰碰碰精品色视频在线观看| 亚洲成人中文字幕在线播放| 一本精品99久久精品77| 欧美性猛交黑人性爽| 国产成+人综合+亚洲专区| cao死你这个sao货| 久久婷婷成人综合色麻豆| 欧美色欧美亚洲另类二区| av在线播放免费不卡| 国产在线精品亚洲第一网站| 成在线人永久免费视频| 一二三四在线观看免费中文在| 69av精品久久久久久| 亚洲欧美日韩东京热| 欧美黑人巨大hd| 黄色 视频免费看| 国产亚洲av嫩草精品影院| 中文亚洲av片在线观看爽| 一本一本综合久久| 亚洲美女黄片视频| 久久久久精品国产欧美久久久| 黄色视频不卡| 亚洲最大成人中文| 国产av又大| 国产亚洲精品第一综合不卡| 亚洲欧洲精品一区二区精品久久久| 老汉色av国产亚洲站长工具| 欧美 亚洲 国产 日韩一| 俺也久久电影网| 日韩欧美国产一区二区入口| 国产久久久一区二区三区| 变态另类丝袜制服| 久久久久国产精品人妻aⅴ院| 国产精华一区二区三区| 最好的美女福利视频网| 亚洲第一电影网av| 久久久久久大精品| 亚洲欧美精品综合一区二区三区| 18禁黄网站禁片午夜丰满| 国产又色又爽无遮挡免费看| 国产成人av激情在线播放| 亚洲九九香蕉| 成人特级黄色片久久久久久久| 无人区码免费观看不卡| 午夜a级毛片| 国产激情欧美一区二区| 国产成人精品无人区| 我的老师免费观看完整版| 狂野欧美激情性xxxx| 99热只有精品国产| 中文资源天堂在线| 黄片大片在线免费观看| 久久人人精品亚洲av| 国产又黄又爽又无遮挡在线| 99国产综合亚洲精品| 精品不卡国产一区二区三区| 制服诱惑二区| 日本免费一区二区三区高清不卡| 99热6这里只有精品| 嫩草影视91久久| 啪啪无遮挡十八禁网站| 老熟妇乱子伦视频在线观看| a级毛片a级免费在线| 一区二区三区国产精品乱码| 天堂√8在线中文| 最新美女视频免费是黄的| 香蕉av资源在线| 久久热在线av| 天堂动漫精品| 啦啦啦韩国在线观看视频| 久久精品综合一区二区三区| 日韩欧美在线乱码| 舔av片在线| 国产免费男女视频| av视频在线观看入口| 777久久人妻少妇嫩草av网站| 亚洲五月天丁香| 国产亚洲精品久久久久久毛片| 日本一二三区视频观看| 亚洲中文字幕一区二区三区有码在线看 | 亚洲精品一区av在线观看| 久久草成人影院| 亚洲片人在线观看| 久久伊人香网站| 欧美黑人欧美精品刺激| 看黄色毛片网站| 一边摸一边抽搐一进一小说| 欧美日本亚洲视频在线播放| 欧美中文综合在线视频| 国产91精品成人一区二区三区| 99热这里只有是精品50| 久久天堂一区二区三区四区| √禁漫天堂资源中文www| 搡老岳熟女国产| 久久久国产成人精品二区| 欧美在线黄色| 美女 人体艺术 gogo| 欧美又色又爽又黄视频| 免费在线观看亚洲国产| 丰满人妻一区二区三区视频av | 狂野欧美激情性xxxx| 国产av不卡久久| 成年版毛片免费区| 免费在线观看成人毛片| 免费电影在线观看免费观看| 两性午夜刺激爽爽歪歪视频在线观看 | www日本在线高清视频| 精品熟女少妇八av免费久了| 国产免费av片在线观看野外av| 91九色精品人成在线观看| 成年人黄色毛片网站| 色噜噜av男人的天堂激情| 久久久久久久久中文| 嫁个100分男人电影在线观看| 美女大奶头视频| 成人欧美大片| 亚洲精品久久国产高清桃花| 午夜福利18| 精品国内亚洲2022精品成人| a级毛片在线看网站| 国产三级在线视频| 免费观看精品视频网站| 亚洲国产精品成人综合色| 久久久久亚洲av毛片大全| 亚洲人成网站高清观看| 亚洲国产精品成人综合色| 人人妻,人人澡人人爽秒播| 91老司机精品| 日韩av在线大香蕉| 人人妻,人人澡人人爽秒播| 精品一区二区三区av网在线观看| cao死你这个sao货| 国产av在哪里看| 一级毛片女人18水好多| 久久天躁狠狠躁夜夜2o2o| 久久国产乱子伦精品免费另类| 99精品在免费线老司机午夜| 男女视频在线观看网站免费 | svipshipincom国产片| 久久中文字幕一级| 一进一出抽搐gif免费好疼| 亚洲欧洲精品一区二区精品久久久| 国产伦人伦偷精品视频| 大型黄色视频在线免费观看| 观看免费一级毛片| 日韩av在线大香蕉| 欧美日本亚洲视频在线播放| 日日夜夜操网爽| 一本久久中文字幕| 男女下面进入的视频免费午夜| 久久精品国产综合久久久|